Clinical trialCLINICALTRIALSToday
Researchers are testing a new drug called BH-30643 for advanced lung cancer patients whose tumors have specific genetic mutations (EGFR or HER2). The study will first figure out the right dose and watch for side effects, then test how well the drug works against the cancer. About 266 patients will participate across multiple hospitals.
WHY IT MATTERSThis trial is now actively recruiting patients with EGFR and/or HER2-mutated advanced NSCLC — if you have this genetic profile and have exhausted standard treatments, you may be eligible to access a potentially new treatment option.
Clinical trialRSS3 days ago
A new drug called masitinib helped ALS patients live longer than expected. In a clinical trial, over 40% of patients treated with masitinib survived for at least 5 years from when their disease started. This is much better than the typical outcome, where fewer than 25% of ALS patients usually live that long.
WHY IT MATTERSIf masitinib gains approval, ALS patients may have access to a treatment that could significantly extend their survival time compared to current standard care.
Clinical trialCLINICALTRIALSApr 6
Researchers are testing a new drug called zipalertinib to see if it helps people with early-stage lung cancer that has specific genetic mutations. Patients who had surgery to remove their tumors will receive either the new drug or a placebo (fake medicine) along with standard chemotherapy. The study wants to find out if zipalertinib can prevent the cancer from coming back better than chemotherapy alone.
WHY IT MATTERSIf you have early-stage NSCLC with uncommon EGFR mutations (like exon 20 insertions) and recently had surgery, this trial offers access to a targeted therapy specifically designed for your mutation type before it becomes widely available.
Clinical trialUNITERAREApr 5
Researchers are testing a new drug called ManNAc to treat primary focal segmental glomerulosclerosis (FSGS), a rare kidney disease that causes scarring and can lead to kidney failure. This is a Phase 2 trial, meaning the drug has already been tested for safety in a small group and now researchers want to see if it actually works to help patients. The trial is now accepting patients and is expected to start in April 2026.
WHY IT MATTERSThis trial offers patients with primary FSGS access to an investigational treatment that may slow or stop kidney damage, with enrollment now open at sites participating in the National Human Genome Research Institute study.
Clinical trialUNITERAREApr 5
Researchers are testing a new drug called CYT107 to help people with HIV who have Kaposi Sarcoma (a type of cancer) and whose immune systems aren't responding well to treatment. CYT107 is designed to boost the immune system to help fight the cancer. This is a Phase 2 trial, meaning it's testing whether the drug works and is safe in a larger group of people. The trial is now accepting patients and will start in April 2026.
WHY IT MATTERSThis trial offers a potential new treatment option for people with HIV-related Kaposi Sarcoma who haven't responded to standard immune-boosting treatments, addressing a significant gap in care for this vulnerable population.
Clinical trialUNITERAREApr 5
Researchers are testing a new drug called pacritinib in people ages 12 and older who have myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms — rare blood disorders where the bone marrow doesn't make enough healthy blood cells. The drug works by blocking several proteins that may be causing these diseases. This is an early-stage study sponsored by the National Cancer Institute that will start recruiting patients in April 2026.
WHY IT MATTERSThis trial offers patients with myelodysplastic syndromes access to a novel multi-targeted kinase inhibitor that may address disease mechanisms not covered by current standard treatments, with enrollment beginning in April 2026.
Clinical trialUNITERAREApr 4
Researchers are testing a new drug called JL15003 to see if it can safely treat glioblastoma, a serious brain cancer that has come back after previous treatment. This is an early-stage study that will check both how safe the drug is and whether it helps patients live longer or feel better. The study is now accepting patients and will run starting in April 2026.
WHY IT MATTERSThis trial offers a potential new treatment option for patients with recurrent glioblastoma, a condition with very limited treatment choices after initial therapy fails.
🔴 BreakingDrug approvalOPENFDAApr 4
The FDA has approved a new drug called FOUNDAYO (orforglipron), made by Eli Lilly. This approval means the medication is now available for patients to use. The drug was officially approved on April 1, 2026.
WHY IT MATTERSWithout information about which rare disease FOUNDAYO treats, we cannot specify the patient impact — the article lacks details about the condition it addresses or which patients are eligible.
Clinical trialUNITERAREApr 3
Researchers are looking for patients with a specific type of brain cancer called glioblastoma (GBM) to test a new drug combination. The study will test a drug called silevertinib combined with temozolomide in patients whose tumors have certain genetic features (unmethylated MGMT and EGFRvIII). This is an early-stage study to see if this combination works better than current treatments.
WHY IT MATTERSThis trial targets newly diagnosed GBM patients with unmethylated MGMT and EGFRvIII mutations—a subgroup with historically poor prognosis—and offers access to a potentially more effective treatment combination before it becomes widely available.
Clinical trialUNITERAREApr 3
Researchers are testing a new drug called Xaluritamig to treat Ewing sarcoma, a rare bone cancer that has come back or stopped responding to previous treatments. This is an early-stage study (Phase 1) that will include children, teenagers, and adults. The study is now accepting patients and is expected to start in April 2026.
WHY IT MATTERSThis trial offers a potential new treatment option for patients with relapsed or refractory Ewing sarcoma, a rare pediatric cancer with limited treatment alternatives after standard therapies fail.
Clinical trialUNITERAREApr 3
Lumos Pharma is testing a new drug called LUM-201 in children who don't produce enough growth hormone naturally. This Phase 3 trial is the final stage of testing before the drug might be approved by the FDA. Researchers are actively recruiting children to participate and see if this treatment helps them grow taller.
WHY IT MATTERSThis is now actively recruiting children with growth hormone deficiency — families interested in potentially accessing LUM-201 before FDA approval should check eligibility requirements and contact the trial sites listed on ClinicalTrials.gov.
Clinical trialUNITERAREApr 3
Prelude Therapeutics is testing a new drug called PRT12396 in people with certain blood cancers called myeloproliferative neoplasms. This is an early-stage study (Phase 1) to see if the drug is safe and how it works in the body. The study is now accepting patients and is expected to start in April 2026.
WHY IT MATTERSThis trial offers access to a potentially new treatment option for patients with myeloproliferative neoplasms who may have limited alternatives, particularly if they have specific subtypes targeted by this drug.
Clinical trialUNITERAREApr 3
Researchers are testing a new drug called elritercept to see if it works better than a standard treatment (epoetin alfa) for anemia in adults with myelodysplastic syndromes (MDS)—a blood disorder where the bone marrow doesn't make enough healthy blood cells. People in this study have low, very low, or intermediate risk MDS and need regular blood transfusions. The trial is now accepting patients.
WHY IT MATTERSThis Phase 3 trial is actively recruiting adults with MDS who require transfusions, offering access to an investigational treatment that may reduce their dependence on blood transfusions.
🔴 BreakingDrug approvalRSSApr 3
The FDA has approved a new drug called Avlayah to treat Hunter syndrome, a rare genetic disease that affects the brain and nervous system. Hunter syndrome happens when the body can't break down certain substances properly, causing serious health problems over time. This approval means patients with Hunter syndrome now have a new treatment option available to help manage the neurologic symptoms of their condition.
WHY IT MATTERSThis is the first FDA approval of Avlayah specifically for the neurologic manifestations of Hunter syndrome, offering patients a new therapeutic option for managing brain and nervous system symptoms that were previously difficult to treat.
🔴 BreakingDrug approvalRSSApr 3
The FDA approved a new drug called Foundayo (orforglipron) on a special fast-track program called the National Priority Voucher program. This is the fifth drug approved through this program, which helps speed up approval for medicines that address important health needs. The program is designed to get helpful new treatments to patients faster.
WHY IT MATTERSThis approval demonstrates the National Priority Voucher program is working to bring new treatment options to patients with rare diseases more quickly than the standard FDA review process.
🔴 BreakingDrug approvalOPENFDAApr 3
The FDA has approved a new drug called FLAVALTA, which contains lidocaine and epinephrine. Lidocaine is a numbing medication, and epinephrine helps control bleeding. This approval means the drug is now available for patients to use, though the specific medical condition it treats is not detailed in this announcement.
WHY IT MATTERSThis approval makes a new numbing and bleeding-control medication available to patients who need it, though the specific rare disease indication requires clarification from your doctor or the full prescribing information.
Drug approvalOPENFDAApr 3
The FDA has approved a new drug made by Baxter Healthcare Corporation. However, the specific name of the drug and what disease it treats are not listed in this announcement. Patients and doctors will need to find more details from official FDA sources to learn what this medication does and who it might help.
WHY IT MATTERSWithout knowing the drug name or indication, we cannot determine specific relevance to any patient population — this announcement lacks critical details needed to assess impact.
Drug approvalOPENFDAApr 3
The FDA has approved a new drug made by TEVA PHARMACEUTICALS, but the article doesn't say what disease it treats or what the drug is called. This approval means the drug is now available for patients, but we need more information to understand who might benefit from it.
WHY IT MATTERSWe cannot determine the specific impact on patients because the drug name and indication are not disclosed in this announcement.
Drug approvalOPENFDAApr 3
The FDA has approved a new drug made by Novo Nordisk, a major pharmaceutical company. However, the specific name of the drug and what disease it treats are not listed in this announcement. Patients and doctors should look for more details from the FDA or Novo Nordisk to understand what this treatment is for and who might benefit from it.
WHY IT MATTERSWithout knowing the drug name or indication, we cannot determine specific relevance to any patient population — more information from the FDA or sponsor is needed to assess impact.
Drug approvalOPENFDAApr 3
The FDA has approved a new drug made by Denali Therapeutics, but the specific name and what disease it treats are not listed in this announcement. The approval was granted on March 24, 2026. Patients and doctors should look for more details from the FDA or the company to understand what this drug does and who it might help.
WHY IT MATTERSWithout knowing the specific drug name and indication, we cannot determine the clinical significance for patients — additional information from the FDA or Denali Therapeutics is needed to assess impact.